塞诺巴作为SCN8A发育性和性脑病变的附加治疗
Cathrine E Gjerulfsen1,2, Madeleine J Oudin3, Francesca Furia1,2
1Department of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Center, Dianalund, Denmark.
Epilepsia
|January 15, 2025
概括
塞诺巴在治疗SCN8A-DEE - - 一种严重的病 - - 中表现有前途. 这种药物显著减少了儿科患者的发作和改善了非发作症状,提供了潜在的新治疗选择.
科学领域:
- 神经学 神经学
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- SCN8A-DEE呈现为严重的,早期发作的,发育迟缓,并且通常对标准治疗有抗性.
- 在SCN8A中,功能获取 (GoF) 变体需要高剂量的通道阻断剂,但对于大多数患者来说,发作自由仍然难以捉摸.
研究的目的:
- 评估在患有SCN8A-DEE.E的患者中赛诺巴酸的疗效和安全性.
- 评估塞诺巴马特对该患者群体中发作频率和非发作相关症状的影响.
主要方法:
- 一项回顾性多中心研究,涉及SCN8A-DEE患者,他们接受了至少六个月的雪诺巴治疗.
- 通过REDCap调查从护理人员或医生收集的数据,SCN8A变体的功能效应从文献或预测工具中得到证实.
主要成果:
- 在12名儿科患者中,有10名 (83%) 患有被认为是GoF SCN8A变异的儿科患者经历了显著的发作减少.
- 两名患者实现了无发作,80%的患者报告了非发作症状的改善,例如警觉性和肌肉强度.
- 50%的患者报告了不良反应,大多数患者自发或随着药物调整而消失.
结论:
- 塞诺巴马特显示出作为SCN8A-DEE安全有效治疗的潜力,即使在幼儿中也是如此.
- 该药物显著降低了的负担,改善了生活质量,表明其作为精准医学方法的实用性.
- 观察到的 cenobamate 的积极结果可能会扩展到其他涉及电压关闭通道变异的遗传性.
相关概念视频
01:14Antiepileptic Drugs: Glutamate Antagonists
276
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
276
01:30Electroconvulsive Therapy
22
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
22
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
320
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
320
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
01:22Alzheimer's Disease: Treatment
161
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
161